Presentation is loading. Please wait.

Presentation is loading. Please wait.

Vivianne Tjan-Heijnen, MJ Pepels, M de Boer, GF Borm, JA van Dijck, CH van Deurzen, EM Adang, MB Menke- Pluymers, PJ van Diest and P Bult On behalf of.

Published byAileen Warner Modified over 9 years ago

Similar presentations

Presentation on theme: "Vivianne Tjan-Heijnen, MJ Pepels, M de Boer, GF Borm, JA van Dijck, CH van Deurzen, EM Adang, MB Menke- Pluymers, PJ van Diest and P Bult On behalf of."— Presentation transcript:

1 Vivianne Tjan-Heijnen, MJ Pepels, M de Boer, GF Borm, JA van Dijck, CH van Deurzen, EM Adang, MB Menke- Pluymers, PJ van Diest and P Bult On behalf of the Dutch Breast Cancer Trialists’ Group (BOOG)‏ Funded by The Netherlands organization for health research and development (ZonMw) Impact of omission of completion ALND or axRT in breast cancer patients with pN1mi or pN0(i+) in SN: results from the Dutch MIRROR study

2 Micrometastases and Isolated tumor cells: Relevant and Robust Or Rubbish? A cohort study from the Netherlands in 2680 early stage breast cancer patients who had undergone a SN procedure in 1997 – 2005 The MIRROR study

3 Background MIRROR study SN procedure has led to an increased detection of isolated tumor cells, pN0(i+), and micrometastases, pN1mi Previous studies - before the SN era - showed conflicting results on the prognostic impact of small nodal metastases

4 MIRROR conclusions, SABCS ‘08 In patients not receiving AST, pN0(i+) and pN1mi were prognostic factors for DFS –pN0(i+): HR 1.50 (95%CI 1.15-1.95) –pN1mi: HR 1.52 (95%CI 1.11-2.09) Our data show that both patients with pN0(i+) and pN1mi benefit from AST –pN0(i+): HR 0.67 (95%CI 0.46-0.96) –pN1mi: HR 0.50 (95%CI 0.35-0.72) De Boer et al. SABCS dec 2008; oral #23

5 Nearly 50% of 795 patients with pN0(i+)(sn) and approximately 15% of 1028 patients with pN1mi(sn) had not received further axillary treatment In 8% of patients with pN0(i+)(sn) or pN1mi(sn) axillary treatment consisted of axRT only Data on safety and efficacy of such strategies regarding axillary recurrence (AR) are, however, lacking Background 2 nd MIRROR analyses

6 Patients selected from the Netherlands Cancer Registry –invasive breast cancer diagnosed 1997 - 2005 –SN procedure –final N-status: pN0, pN0(i+) or pN1mi –favorable characteristics (Dutch guidelines 2002)‏ tumor size ≤ 1 cm irrespective of grade OR tumor size 1-3 cm and grades I-II Patients and methods

7 no pathology review macrometastases unfavorable tumor characteristics other reasons n = 3205 selected from Netherlands Cancer Registry n = 2680 inclusion after central pathology review Accrual SN only N= 1218 cALND N= 1314 axRT N= 148

8 no pathology review macrometastases unfavorable tumor characteristics other reasons n = 3205 selected from Netherlands Cancer Registry n = 2680 inclusion after central pathology review Accrual SN only N= 1218 cALND N= 1314 axRT N= 148

9 no pathology review macrometastases unfavorable tumor characteristics other reasons n = 3205 selected from Netherlands Cancer Registry n = 2680 inclusion after central pathology review Accrual SN only N= 1218 cALND N= 1314 axRT N= 148 Present analysis: categorized by SN-status

10 SN only n= 1218 cALND n= 1314 axRT n= 148 P-value SN only vs cALND / RT SN status pN060%9%3% pN0(i+)28%30%36%<0.0001 pN1mi12%61% Baseline characteristics

11 SN only n= 1218 cALND n= 1314 axRT n= 148 P-value SN only vs cALND / RT Tumor size ≤ 1 cm36%25%24% <0.0001 1.1-2.0 cm54%58%64% 2.1-3.0 cm10%18%13% Baseline characteristics

12 SN only n= 1218 cALND n= 1314 axRT n= 148 P-value SN only vs cALND / RT Adjuvant systemic therapy No87%45%39% <0.0001 Yes13%55%61% Baseline characteristics

13 SN only n= 1218 cALND n= 1314 axRT n= 148 P-value SN only vs cALND / RT RT breast No29%35%5% 0.09 Yes71%65%95% Baseline characteristics

14 Axillary recurrence rate in all included patients 5-yrs AR 1.7%

15 Objectives 1.To determine the impact of omission of axillary therapy on 5-yrs AR rate by SN status 2.To determine the efficacy of axRT vs cALND 3.To determine other factors predictive for AR

16 Objectives 1.To determine the impact of omission of axillary therapy on 5-yrs AR rate by SN status

17 VariableN 5-yrs AR HR95 % CI pN0(sn) * cALND1251.6%1.00 pN0(sn) * SN only7322.3%1.080.23-4.98 HR, corrected for age, tumor size, differentiation grade, hormone receptor status, adjuvant systemic therapy, radiotherapy to the breast MV analysis: axillary recurrence (AR)

18 VariableN 5-yrs AR HR95 % CI pN0(i+)(sn) * cALND/axRT4500.9%1.00 pN0(i+)(sn) * SN only3452.0%2.390.67-8.48 HR, corrected for age, tumor size, differentiation grade, hormone receptor status, adjuvant systemic therapy, radiotherapy to the breast MV analysis: axillary recurrence (AR)

19 VariableN 5-yrs AR HR95 % CI pN1mi(sn) * cALND / axRT8871.0%1.00 pN1mi(sn) * SN only1415.0%4.391.46-13.24 HR, corrected for age, tumor size, differentiation grade, hormone receptor status, adjuvant systemic therapy, radiotherapy to the breast MV analysis: axillary recurrence (AR)

20 Conclusions For low-risk patients with pN0(sn), we confirm the safety of no further axillary treatment For low-risk patients with pN0(i+)(sn), omission of axillary treatment resulted in an increased hazard ratio (HR 2.39) for AR, though statistically not significant For patients with pN1mi(sn), omission of axillary treatment resulted in a significantly increased AR rate (5% at 5 yr, HR 4.39)

21 Objectives 1.To determine the impact of omission of axillary therapy on 5-yrs AR rate by SN status 2.To determine the efficacy of axRT vs cALND

22 VariableN 5-years AR pN0(i+)(sn) * cALND3961.0% pN0(i+)(sn) * axRT540% pN0(i+)(sn) * SN3452.0% pN1mi(sn) * cALND7931.1% pN1mi(sn) * axRT940% pN1mi(sn) * SN1415.0% Efficacy of axRT

23 Conclusion An AR rate of 0% at 5-years in patients treated with axRT is provocative, challenging the current recommendation of cALND However, more data on axRT are needed for a meaningful statistical analysis and before firm conclusions can be drawn (e.g. AMAROS study)

24 Axillary recurrence rate in pN1mi(sn) SN only: HR 4.39 (95% CI 1.46 –13.24)

25 Objectives 1.To determine the impact of omission of axillary therapy on 5-yrs AR rate by SN status 2.To determine the efficacy of axRT vs cALND 3.To determine other factors predictive for AR

26 VariableHR95 % CIP-value Tumor size8.621.38 – 53.840.021 MV analysis: 5-yrs AR rate pN1mi(sn)

27 VariableHR95 % CIP-value Tumor size8.621.38 – 53.840.021 Histological grade III25.051.26 – 497.180.035 MV analysis: 5-yrs AR rate pN1mi(sn)

28 VariableHR95 % CIP-value Tumor size8.621.38 – 53.840.021 Histological grade III25.051.26 – 497.180.035 Negative ER / PgR status4.961.48 – 16.620.010 MV analysis: 5-yrs AR rate pN1mi(sn)

29 VariableHR95 % CIP-value Tumor size8.621.38 – 53.840.021 Histological grade III25.051.26 – 497.180.035 Negative ER / PgR status4.961.48 – 16.620.010 No systemic therapy1.360.47 – 3.990.572 MV analysis: 5-yrs AR rate pN1mi(sn)

30 VariableHR95 % CIP-value Tumor size8.621.38 – 53.840.021 Histological grade III25.051.26 – 497.180.035 Negative ER / PgR status4.961.48 – 16.620.010 No systemic therapy1.360.47 – 3.990.572 No breast radiotherapy1.010.36 – 2.880.979 MV analysis: 5-yrs AR rate pN1mi(sn)

31 Conclusion Tumor size, grade, and hormone receptor status were predictive for AR in patients with pN1mi(sn) Omission of adjuvant systemic therapy resulted in an increased hazard ratio for AR, though statistically not significant Radiotherapy on the breast had no impact on AR rate

32 Take Home Message For patients with pN0(sn), omission of axillary therapy is safe and standard policy For patients with pN0(i+)(sn), omission of axillary therapy may only be safe in the presence of otherwise favorable tumor characteristics We recommend completion axillary treatment in patients with pN1mi(sn) to reduce the AR rate

33 Take Home Message More data are needed on the efficacy of axRT, though results are provocative Unfavorable tumor size, grade, and hormone receptor status should be taken into account when considering ‘SN only’ in patients with pN0(i+)(sn) or pN1mi(sn)

34 Project Leader: Vivianne Tjan-Heijnen, Maastricht University Medical Centre Study Coordinators: Maaike de Boer, Maastricht University Medical Centre Manon Pepels, Maastricht University Medical Centre Steering Committee: Peter Bult, Radboud University Nijmegen Medical Centre Paul van Diest, University Medical Centre Utrecht Jos van Dijck, Comprehensive Cancer Centre East, Nijmegen Eddy Adang, Radboud University Nijmegen Medical Centre Hans Nortier, Leiden University Medical Centre Emiel Rutgers, National Cancer Institute / A. van Leeuwenhoek Hospital, Amsterdam Caroline Seynaeve, University Medical Centre Rotterdam Marian Menke-Pluymers, University Medical Centre Rotterdam Central Pathology Review: Peter Bult, Radboud University Nijmegen Medical Centre Carolien van Deurzen, University Medical Centre Utrecht Paul van Diest, University Medical Centre Utrecht Statistical Analysis: George Borm, Radboud University Nijmegen Medical Centre Wim Lemmens, Radboud University Nijmegen Medical Centre Participating Centres: All Dutch Pathology Laboratories (n = 60)‏ All Dutch Hospitals (n = 113)‏ All Dutch Comprehensive Cancer Centres (n = 8)‏ Data Management: Comprehensive Cancer Centre East Jolanda van Beek - Schoester Supported by: Dutch Breast Cancer Trialists’ Group (BOOG)‏ Funded by: The Netherlands organization for health research and development (ZonMw)‏ Steering group - acknowledgements

Download ppt "Vivianne Tjan-Heijnen, MJ Pepels, M de Boer, GF Borm, JA van Dijck, CH van Deurzen, EM Adang, MB Menke- Pluymers, PJ van Diest and P Bult On behalf of."

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Giuliano Pre-SSO mins ASCO Z mins

Giuliano Pre-SSO mins ASCO Z mins
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.

Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.

SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.
S ENTINEL L YMPH N ODE M ICROMETASTASIS IN B REAST C ANCER Anthony Fong Yan Chai Hospital.

S ENTINEL L YMPH N ODE M ICROMETASTASIS IN B REAST C ANCER Anthony Fong Yan Chai Hospital.
Sentinel Lymph Node Dissection (SND)

Sentinel Lymph Node Dissection (SND)
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.
Hot topics in breast radiotherapy Mark Beresford.

Hot topics in breast radiotherapy Mark Beresford.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
The All Breast Cancer Report was published in October 2009 breastscreen/research.html#breast- cancer-report.

The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
The influence of Breast Cancer Pay for Performance Initiatives on breast cancer survival and performance measures: a pilot study in Taiwan Raymond NC Kuo,

The influence of Breast Cancer Pay for Performance Initiatives on breast cancer survival and performance measures: a pilot study in Taiwan Raymond NC Kuo,
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Similar presentations

Ads by Google